Ivabradina Tecnigen

Ivabradine, the active ingredient in Ivabradina Tecnigen, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate without affecting myocardial contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics and responsive technical support.

Ivabradine acts on the cardiac If current and is used in conditions where heart‑rate reduction improves symptoms.

Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate to improve ventricular filling and reduce hospitalizations. Patients intolerant of beta‑blockers: provides heart‑rate control when beta‑blockers are contraindicated or not tolerated.

Ivabradine may be associated with several adverse reactions, which are grouped by frequency and clinical significance.

Common Side Effects: - Luminous phenomena (phosphenes): transient visual sensations, especially in low light. - Bradycardia: resting heart rate below 50 bpm. - Headache: mild to moderate intensity. - Dizziness or vertigo: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe bradycardia with syncope: may require discontinuation. - Atrial fibrillation: new‑onset irregular rhythm. - Significant hypotension: symptomatic low blood pressure. - Elevated hepatic transaminases (rare): potential liver injury.

Before initiating ivabradine, several safety considerations should be evaluated.

Assess resting heart rate: ensure rate ≥ 70 bpm before starting. Avoid in severe hepatic impairment: lack of safety data. Monitor for symptomatic bradycardia: discontinue if heart rate falls below 50 bpm or patient experiences dizziness. Caution with concomitant CYP3A4 inhibitors: may increase plasma concentrations. Store at room temperature: keep in original container, protect from moisture and light.

Ivabradine interacts with several medicines that can alter its plasma level or additive heart‑rate effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause excessive bradycardia. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, diltiazem, verapamil): risk of profound bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampicin, carbamazepine): may reduce efficacy. - Digitalis glycosides: may increase risk of bradycardia. - Antihypertensive agents: may enhance hypotensive effect.